Rodents treated with GLP-1 receptor agonists demonstrated reduced joint inflammation, decreased synovial proliferation, and lower levels of inflammatory cytokines compared to untreated controls
Summary of phase 2 clinical trials of GLP1R agonists for PD Ex-4: exenatide-4, mTOR: mechanistic target of rapamycin, IRS1: insulin receptor substrate 1, MDS-UPDRS: Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale, PD: Parkinsons disease, PKB: protein kinase B, DAergic: dopaminergic, GLP1R: glucagon-like peptide-1 receptor.
Dulaglutida (Trulicity): Inyeccin semanal para diabetes tipo 2, con indicacin de reduccin de riesgo cardiovascular
Pay attention to the tier the medication is in, as this will affect your out-of-pocket costs
For example: At 0.25 mg semaglutide from a 5 mg/mL vial, you only draw 0.05 mL, delivering just 0.025 mg (25 mcg) of B12 At 2.4 mg from the same vial, you draw 0.48 mL, delivering 0.24 mg (240 mcg) of B12 The recommended daily intake of B12 for adults is 2.4 mcg